Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer

被引:13
作者
He, Kewen [1 ,2 ]
Barsoumian, Hampartsoum B. [1 ]
Sezen, Duygu [1 ,3 ]
Puebla-Osorio, Nahum [1 ]
Hsu, Ethan Y. [1 ]
Verma, Vivek [4 ]
Abana, Chike O. [1 ]
Chen, Dawei [2 ]
Patel, Roshal R. [5 ]
Gu, Meidi [6 ]
Cortez, Maria Angelica [1 ]
Welsh, James W. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Shandong Univ, Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol,Shandong Canc Hosp, Jinan, Peoples R China
[3] Koc Univ, Dept Radiat Oncol, Sch Med, Istanbul, Turkey
[4] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA
[5] Albany Med Coll, Albany, NY 12208 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
美国国家卫生研究院;
关键词
radiation therapy; immunotherapy; metastatic cancer; adaptive immunity; memory effect; TERTIARY LYMPHOID STRUCTURES; T-CELL RESPONSES; COMBINED IMMUNOTHERAPY; ANTITUMOR IMMUNITY; LUNG-CANCER; RADIOTHERAPY; TUMOR; ONCOLOGY; COMBINATION; IRRADIATION;
D O I
10.3389/fonc.2021.737425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiation therapy (RT) is emerging as an interventional modality in the cancer-immunity cycle, augmenting the activation of an adaptive immune response against tumors. RT, particularly in combination with immunotherapy, can enhance immune memory effects and shape the tumor-directed T-cell populations. However, a single cycle of RT delivered to a limited number of polymetastatic lesions is rarely sufficient to achieve systemic control. We hypothesize that several rounds of RT, akin to several rounds of immunotherapeutic drugs, is likely to provide greater clinical benefit to patients with metastatic disease. We propose that the repeated exposure to tumor antigens released by "pulsed-RT" (i.e., treating 2-4 tumor lesions with 3 irradiation cycles given one month apart) may amplify the adaptive immune response by expanding the tumor-specific T-cell receptor repertoire, the production of high-affinity tumor antibodies, and the generation of memory lymphocytes and thereby improve immune control of systemic disease.
引用
收藏
页数:9
相关论文
共 69 条
  • [51] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
    Palma, David A.
    Olson, Robert
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander V.
    Haasbeek, Cornelis
    Mulroy, Liam
    Lock, Michael
    Rodrigues, George B.
    Yaremko, Brian P.
    Schellenberg, Devin
    Ahmad, Belal
    Griffioen, Gwendolyn
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Bauman, Glenn S.
    Warner, Andrew
    Senan, Suresh
    [J]. LANCET, 2019, 393 (10185) : 2051 - 2058
  • [52] Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
    Rodriguez-Ruiz, M. E.
    Perez-Gracia, J. L.
    Rodriguez, I
    Alfaro, C.
    Onate, C.
    Perez, G.
    Gil-Bazo, I
    Benito, A.
    Inoges, S.
    Lopez-Diaz de Cerio, A.
    Ponz-Sarvise, M.
    Resano, L.
    Berraondo, P.
    Barbes, B.
    Martin-Algarra, S.
    Gurpide, A.
    Sanmamed, M. F.
    de Andrea, C.
    Salazar, A. M.
    Melero, I
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (05) : 1312 - 1319
  • [53] Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
    Rudqvist, Nils-Petter
    Pilones, Karsten A.
    Lhuillier, Claire
    Wennerberg, Erik
    Sidhom, John-William
    Emerson, Ryan O.
    Robins, Harlan S.
    Schneck, Jonathan
    Formenti, Silvia C.
    Demaria, Sandra
    [J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) : 139 - 150
  • [54] Tertiary lymphoid structures in the era of cancer immunotherapy
    Sautes-Fridman, Catherine
    Petitprez, Florent
    Calderaro, Julien
    Fridman, Wolf Herman
    [J]. NATURE REVIEWS CANCER, 2019, 19 (06) : 307 - 325
  • [55] Schnell A, 2020, CELL RES, V30, P285, DOI 10.1038/s41422-020-0277-x
  • [56] Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
    Shaverdian, Narek
    Lisberg, Aaron E.
    Bornazyan, Krikor
    Veruttipong, Darlene
    Goldman, Jonathan W.
    Formenti, Silvia C.
    Garon, Edward B.
    Lee, Percy
    [J]. LANCET ONCOLOGY, 2017, 18 (07) : 895 - 903
  • [57] Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells
    Shinomiya, N
    Kuno, Y
    Yamamoto, F
    Fukasawa, M
    Okumura, A
    Uefuji, M
    Rokutanda, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 767 - 777
  • [58] Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy
    Takeshima, Tsuguhide
    Chamoto, Kenji
    Wakita, Daiko
    Ohkuri, Takayuki
    Togashi, Yuji
    Shirato, Hiroki
    Kitamura, Hidemitsu
    Nishimura, Takashi
    [J]. CANCER RESEARCH, 2010, 70 (07) : 2697 - 2706
  • [59] Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
    Tang, Chad
    Welsh, James W.
    de Groot, Patricia
    Massarelli, Erminia
    Chang, Joe Y.
    Hess, Kenneth R.
    Basu, Sreyashi
    Curran, Michael A.
    Cabanillas, Maria E.
    Subbiah, Vivek
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Karp, Daniel
    Gomez, Daniel R.
    Diab, Adi
    Komaki, Ritsuko
    Heymach, John V.
    Sharma, Padmanee
    Naing, Aung
    Hong, David S.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1388 - 1396
  • [60] Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
    Theelen, Willemijn S. M. E.
    Peulen, Heike M. U.
    Lalezari, Ferry
    van der Noort, Vincent
    de Vries, Jeltje F.
    Aerts, Joachim G. J. V.
    Dumoulin, Daphne W.
    Bahce, Idris
    Niemeijer, Anna-Larissa N.
    de Langen, Adrianus J.
    Monkhorst, Kim
    Baas, Paul
    [J]. JAMA ONCOLOGY, 2019, 5 (09) : 1276 - 1282